The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis

Abstract

After approval by the European Union in 1996 of interferon-beta for treatment of relapsing-remitting multiple sclerosis (RRMS), 862 patients in Denmark have received treatment (by April 1999), and 304 of those were enrolled into an open labelled randomised trial to compare the efficacy and tolerability of treatment with interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day and interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week. Primary and secondary end-points included: (1) the relapse rate, (2) tolerability, (3) neutralizing antibody formation using the same specialised laboratory and validated assay, (4) time to first relapse, (5) time to sustained progression, and (6) number of gadolinium-enhancing lesions in T1-weighted MRI and the total lesion load in T2-weighted MRI. All the records are kept in a nationwide clinical database connected with the Danish Multiple Sclerosis Registry. The randomised trial will be completed by the end of 1999, and the results are not yet available. The annual relapse rate in all treated patients until April 1999 was 0.73, the annual rate of steroid treated relapses was 0.21. By 1 April 1999 8.8% of the patients had discontinued treatment and 10.4% had changed to another interferon-beta preparation. It has been planned to extend the follow-up of all patients treated according to the Danish National Protocol for a period of several years. The continuous and nation-wide registration of the course of the disease in interferon-beta treated RRMS patients may provide valuable knowledge of the treatment-modified long-term course of the disease in a cohort of patients, selected on the basis of well-defined criteria.

Keywords

multiple sclerosis drug therapy interferon beta therapeutic use randomized controlled trials databases registries

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 43: 655-661 .

Paty DW , Li DK. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group . Neurology 43: 662-667 .

Anonymous . (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Neurology 45: 1277-1285 .

Koch-Henriksen N. (1999) The Danish Multiple Sclerosis Registry: a 50-year follow-up . Mult Sclerosis 5: 293-296 .

Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 39: 285-294 .

Munafo A , Trinchard-Lugan I , Nguyen TXQ , Buraglio M. (1998) Comparative pharmaco-kinetics and pharmaco-dynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration . Eur J Neurol 5: 187-193 .

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 13: 227-231 .

Anonymous . (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group . Lancet 352: 1498-1504 .

European Study Group on interferon beta-1b in secondary progressive MS. (1998) Placebo-controlled multi-centre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 352: 1491-1497 .

10.

Statens Institut for Medincinsk Teknologivurdering. (1999) Beta-interferonbehandling ved dissemineret sklerose. Sundhedsstyrelsen: Copenhagen. (Summary in English).